BioSpace News Archive

AmerisourceBergen Specialty Group, LLC is issuing notice to individuals who may have been impacted by a data security incident.

FSD Pharma Inc. is pleased to announce that it has entered into an investor relations services agreement with IR Agency LLC effective May 22, 2024.

Nicox SA, an international ophthalmology company, convenes an ordinary shareholder meeting on Friday June 28th, 2024 at 2:30 pm CEST in the offices of BuroClub – Drakkar 2 – Bâtiment D – 2405 route des Dolines – 06560 Valbonne Sophia Antipolis – France.

Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been dosed in the Phase 1/2 trial of TSN1611 for the treatment of KRAS G12D mutant solid tumors in the United States.

Shanghai Henlius Biotech, Inc. and Organon announced that the European Medicines Agency has validated the marketing authorization applications for HLX14, an investigational Prolia® and Xgeva® biosimilar.

Verastem Oncology announced that it has initiated the rolling submission of a New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval of the combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer, who received at least one prior systemic therapy.

Genelux Corporation announced the pricing of an underwritten offering of 6,875,000 shares of its common stock and accompanying warrants to purchase 6,875,000 shares of its common stock at a combined offering price of $4.00 per share and accompanying warrant, in each case before underwriting discounts and commissions.

Astria Therapeutics, Inc., a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.

Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company developing N-myristoyltransferase (NMT) inhibitors as targeted therapies for the treatment of hematologic cancers and solid tumors.

G-protein coupled receptor family C group 5 member D, or GPRC5D, has come up as a protein being considered for the development of therapeutic interventions in cancer